Barrett-Connor E
Department of Family and Preventive Medicine, University of California, San Diego, La Jolla 92093, USA.
Ann N Y Acad Sci. 2001 Dec;949:295-303. doi: 10.1111/j.1749-6632.2001.tb04036.x.
Raloxifene, a selective estrogen receptor modulator (SERM), was designed to have the expected benefits of long-term estrogen replacement therapy without the risks. This paper reviews the clinical trial evidence for raloxifene benefits and risks, and how they compare with those of hormone replacement therapy (HRT) and relate to the choices of postmenopausal women.
雷洛昔芬是一种选择性雌激素受体调节剂（SERM），其设计目的是在无风险的情况下获得长期雌激素替代疗法的预期益处。本文回顾了雷洛昔芬益处和风险的临床试验证据，以及它们与激素替代疗法（HRT）相比情况如何，以及与绝经后女性选择的关系。
